4,901 trials
Non-squamous, Non-Small-Cell Lung Cancer · Neoplasms
Primary: Part 1 - Number of Patients With Dose Limiting Toxicity (DLT) Within the First Cycle of Treatment — 1; 0; 0; 1 Participants
Substance Use Disorders · Methamphetamine Abuse · Methamphetamine Intoxication
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) — 1; 1; 2; 4 Participants
Pharmacokinetics · Solid Tumor · Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT) — 0; 0; 1; 0 Participants
Solid Tumor
Primary: The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218 — 1.2 mg/kg
Healthy
Primary: Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 12334.87; 4500.05 hour * nanomole /…
Healthy
Primary: Area Under the Concentration-time Curve of BI 1810631 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 4240; 5680; 4060; 5410 hour…
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Chronic Plantar Fasciitis
Primary: Visual Analog Scale Score - General Heel Tenderness — 46.7; 47.5 score on a scale
Hepatic Impairment
Primary: Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of M2951 — 186; 232; 362 hour*nanogram per milliliter (h*ng/mL)
Nipah Virus Infection
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Product Administration — 1; 1; 0; 4 Participants
Non-alcoholic Steatohepatitis · Hepatic Impairment
Primary: Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Efinopegdutide — 143; 152; 146 hr*μg/mL
ALL, Childhood · Lymphoblastic Leukemia, Acute, Childhood · Lymphoblastic Leukemia, Acute
Primary: Number of Participants With Dose Limiting Toxicities as a Measure of Safety and Tolerability — 0; 2; 0; 1 Participants
Advanced Malignant Solid Neoplasm · Fibrolamellar Carcinoma · Metastatic Malignant Solid Neoplasm
Primary: Dose-limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Midazolam and Its Metabolite…
Acute Myelogenous Leukemia
Primary: The Dose of Decitabine That Can be Safely Given With Vorinostat, Fludarabine, High Dose Cytarabine and G-CSF (FLAG) — 3; 20; 12; 0 Participants